Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Schellhammer

Showing results (301-310 of 326) with videos related to

Pageof 33
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerEric J Small, Paul F Schellhammer, Celestia S Higano, et al.
Cancer|November 15, 1996
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Biometrics|May 24, 2003
Data reduction using a discrete wavelet transform in discriminant analysis of very high dimensionality dataYinsheng Qu, Bao-Ling Adam, Mark Thornquist, et al.
Urology|September 25, 1997
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Journal of Proteome Research|January 9, 2009
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluidsKrista Y White, Lucy Rodemich, Julius O Nyalwidhe, et al.
Urology|April 1, 1996
A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter studyP Narayan, J Trachtenberg, H Lepor, et al.
Cancer Research|July 5, 2002
Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy menBao-Ling Adam, Yinsheng Qu, John W Davis, et al.
Urology|April 10, 1999
Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety StudyX J Yang, K Lecksell, K Short, et al.
Urology|July 1, 1996
Bropirimine immunotherapy of upper urinary tract carcinoma in situM F Sarosdy, L L Pisters, P R Carroll, et al.
The Journal of Urology|May 1, 1997
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockadeP F Schellhammer, P Venner, G P Haas, et al.
Pageof 33

Showing results (301-310 of 326) with videos related to

Sort By:
Pageof 33
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerEric J Small, Paul F Schellhammer, Celestia S Higano, et al.
Cancer|November 15, 1996
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Biometrics|May 24, 2003
Data reduction using a discrete wavelet transform in discriminant analysis of very high dimensionality dataYinsheng Qu, Bao-Ling Adam, Mark Thornquist, et al.
Urology|September 25, 1997
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Journal of Proteome Research|January 9, 2009
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluidsKrista Y White, Lucy Rodemich, Julius O Nyalwidhe, et al.
Urology|April 1, 1996
A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter studyP Narayan, J Trachtenberg, H Lepor, et al.
Cancer Research|July 5, 2002
Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy menBao-Ling Adam, Yinsheng Qu, John W Davis, et al.
Urology|April 10, 1999
Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety StudyX J Yang, K Lecksell, K Short, et al.
Urology|July 1, 1996
Bropirimine immunotherapy of upper urinary tract carcinoma in situM F Sarosdy, L L Pisters, P R Carroll, et al.
The Journal of Urology|May 1, 1997
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockadeP F Schellhammer, P Venner, G P Haas, et al.
Pageof 33